<DOC>
	<DOCNO>NCT00934570</DOCNO>
	<brief_summary>The purpose study assess sustainability two-year intervention aim improve body mass index ( BMI ) metabolic vascular health obese youth . The study compare lifestyle change diet exercise alone change lifestyle combination metformin medication . An initial intensive exercise program also compare standard exercise program . Hypothesis : Metformin therapy combination intensive lifestyle intervention obese child adolescent associate reduced rate weight gain , improve BMI , body composition , physical activity , physical fitness , insulin sensitivity , blood lipid profile , adipocytokines vascular function .</brief_summary>
	<brief_title>Activity Metformin Intervention Obese Adolescents</brief_title>
	<detailed_description>This study assess sustainability two-year intervention degree improvement body mass index ( BMI ) reduction risk factor type 2 diabetes diabetes related cardiovascular disease , well evaluate additive effect metformin ( GlumetzaTM 500 mg Extended Release Tablets ) compare initial intensive exercise program standard exercise program . The study recruit obese youth risk type 2 diabetes cardiovascular disease .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Obese adolescent define BMI great 95th percentile age gender Metformin naive subject Elevated fast plasma glucose ≥ 6.0 mmol/L 2 hour plasma glucose ≥ 11.1 mmol/L standard glucose load A1C &gt; 6.0 % Medication `` counter '' drug , oral contraceptive pill thyroid hormone replacement Smoking Pregnancy Renal insufficiency ( serum creatinine &gt; upper limit normal ) Hepatic dysfunction ( &gt; 1.5 time upper limit normal AST ALT ) Latex Allergy Hypersensitivity metformin ingredient Breast feeding Subjects history lactic acidosis Abnormal creatinine clearance HIV , HBV , HCV infection Drug alcohol abuse Severe mental disorder Subjects plan radiologic exam involve i.v . injection iodinate contract material Participation another clinical trial Significant history presence cardiovascular , pulmonary , gastrointestinal , immunologic , endocrine , neurologic disorder Malignant disease Previous exposure pharmaceutical antidiabetic agent</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Metformin</keyword>
	<keyword>Physical activity</keyword>
	<keyword>Cardiovascular health</keyword>
</DOC>